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Abstract
Concurrent chemoradiation with 5-fluorouracil (5-FU) is widely accepted for cancer treatment. However, the interactions
between radiation and 5-FU remain unclear. Here, we evaluated the influence of local irradiation on the pharmacokinetics of
5-FU in rats. The single-fraction radiation was delivered to the whole pelvic fields of Sprague-Dawley rats after computerized
tomography-based planning. 5-FU at 100 mg/kg was prescribed 24 hours after radiation. A high-performance liquid
chromatography system was used to measure 5-FU in the blood. Matrix metalloproteinase-8 (MMP-8) inhibitor I was
administered to examine whether or not RT modulation of 5-FU pharmacokinetic parameters could be blocked. Compared
with sham-irradiated controls, whole pelvic irradiation reduced the area under the concentration versus time curve (AUC) of
5-FU in plasma and, in contrast, increased in bile with a radiation dose-dependent manner. Based on protein array analysis,
the amount of plasma MMP-8 was increased by whole pelvic irradiation (2.8-fold by 0.5 Gy and 5.3-fold by 2 Gy) in
comparison with controls. Pretreatment with MMP-8 inhibitor reversed the effect of irradiation on AUC of 5-FU in plasma.
Our findings first indicate that local irradiation modulate the systemic pharmacokinetics of 5-FU through stimulating the
release of MMP-8. The pharmacokinetics of 5-FU during concurrent chemoradiaiton therapy should be rechecked and the
optimal 5-FU dose should be reevaluated, and adjusted if necessary, during CCRT.
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Introduction
Radiation therapy (RT) is used as an effective local treatment
modality to inhibit cell proliferation, induce cell death and suppress
tumor growth [1]. To improve the treatment outcome, in terms of both
locoregional control and survival, the concurrent use of chemotherapy
during radiation therapy (CCRT) is now the standard treatment for
various malignancies, especially locally advanced cancers. Among the
drugs used to enhance RT effect, 5-fluorouracil (5-FU) is one of the
most commonly used chemotherapeutic agents of CCRT [2,3,4,5].
In the past, RT was solely used as a local treatment and its effect was
estimated by local effect model [6]. However, growing evidence shows
that irradiation has direct DNA damage-dependent effects as well as
sending signals to neighboring cells. The reactions of non-irradiated
cells responding to signals produced by neighboring irradiated cells are
termed the bystander effect [7,8]. Furthermore, longer-range effects
occurring within or between tissues are also reported and are termed
abscopal, out-of-field or distant bystander responses [9]. Several
molecules play roles in bystander signaling that involve stress responses
and cell-cell signaling, however, none of them is specific to radiation
exposure. Several studies show the alterations of plasma substance
levels responding to radiation, such as interleukin 6 (IL-6) [10], IL-8
[11], transforming growth factor-beta 1 (TGF-b1) [12], tumor necrosis
factor a (TNF-a) [13], reactive oxygen species [14] and reactive
nitrogen species [15]. Yet, no strong evidence for causal relationships of
these molecules is provided. Recently, we reported that abdominal
irradiation could significantly modulate the systemic pharmacokinetics
of 5-FU at 0.5 Gy, off-target area in clinical practice, and at 2 Gy, the
daily treatment dose for target treatment in an experimental rat model
[16]. Additionally, the results from a clinical investigation showed that
colorectal cancer patients with lower AUC of 5-FU during adjuvant
chemotherapy had lower disease-free survival [17]. Taken together,
these lines of evidence support the importance and necessity to search
for the mediators responsible for the unexpected effect of local RT on
systemic pharmacokinetics of chemotherapeutic agents, such as 5-FU.
In the present study, we investigated possible soluble mediators
involved in the effect of localized whole pelvic RT, with liver sparing,
on the pharmacokinetics of 5-FU in rats.
Results
Plasma pharmacokinetic parameters of 5-FU and whole
pelvic irradiation
To verify that local RT modulated the systemic pharmacoki-
netics of 5-FU, we established an experimental model using CT-
based planning and pelvic irradiation in rats, and integrated it into
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e21000a pharmacokinetic assay system. Intriguingly, we found that pelvic
irradiation markedly reduced the AUC of 5-FU in rats by 17.6%
at 0.5 Gy (P=0.019) and 21.5% at 2 Gy (P=0.008) (Fig. 1A). Of
special interest, the radiation at 2 Gy to the rat whole pelvis
simulated the daily treatment dose to a human, whereas the low-
dose radiation (0.5 Gy) simulated the dose deposited in the
generous, off-target area in clinical practice. As shown in Table 1,
pelvic irradiation significantly decreased mean residence time
(MRT), and by contrast, increased the clearance value of 5-FU
when compared to non-irradiated controls. There was no
significant difference in the values of half-life (T1/2), maximum
observed plasma concentration (Cmax) or volume of distribution
at steady state (Vss) within the tested groups.
Bile pharmacokinetic parameters of 5-FU and whole
pelvic irradiation
We found that pelvic irradiation markedly increased the AUC
of 5-FU in bile of rats by 25.1% at 0.5 Gy and 30.6% at 2 Gy
(Fig. 1B). Pelvic irradiation significantly decreased Cmax and
clearance value, and in contrast, increased MRT and Vss of 5-FU,
when compared to non-irradiated controls. Of interest, 2-Gy
irradiation decreased Cmax, and in contrast, increased MRT
(P=0.008) and Vss (P=0.015) of 5-FU to an extent greater than
that of the 0.5-Gy group. There was no statistically significant
difference between the 0.5-Gy and control groups for Cmax and
Vss. Furthermore, no significant difference in T1/2 was noted
among the three groups (Table 2).
Hepatic function after RT or 5-FU treatment
The serum concentrations of alanine aminotransferase (ALT)
levels were no significant difference between the 5-FU-treated,
2Gy-treated, 0.5 Gy followed by 5-FU-treated and 2 Gy followed
by 5-FU-treated and control groups (Fig. 2).
The cytokines respond to RT or 5-FU in the plasma
Compared with the control group, there were no significant
differences between the RT 2Gy alone, 5-FU alone, RT 0.5 Gy
followed by 5-FU and RT 2 Gy followed by 5-FU group in the
levels of transforming growth factor-beta 1 (TGF-b1) and tumor
necrosis factor a (TNF-a) (Fig. 3A and 3B).
Alteration of soluble factors in plasma caused by whole
pelvic irradiation
To assess the changes in profile of soluble factors involved with
whole pelvic irradiation, rat plasma samples were collected and
subjected to a cytokine antibody array assay (Fig. 4). In
comparison with control (untreated) group (Fig. 4A) and 5-FU
alone group (Fig. 4C), the observable dose-dependent changes in
plasma levels of soluble factors included matrix metalloproteinase-
8 (MMP-8), monocyte chemoattractant protein 1 (MCP-1),
cytokine-induced neutrophil chemoattractant -1 (CINC-1) and
tissue inhibitor of metalloproteinase-1 (TIMP-1). Among these
factors, only the increase in MMP-8 level was consistent in
triplicate experiments. Compared with control groups, RT 2Gy
Figure 1. The area under the concentration vs. time curve (AUC) of 5-fluorouracil (5-FU) 100 mg/kg administered to rats in the
control, 0.5-Gy and 2-Gy groups. The transverse axis illustrates time in minutes and the vertical axis represents the concentration of 5-FU. (A)
Plasma. (B) Bile. Each group’s data was collected from six rats.
doi:10.1371/journal.pone.0021000.g001
Table 1. Plasma pharmacokinetics of 5-fluorouracil (100 mg/
kg, i.v.) in rats after whole pelvic irradiation with or without
0.5 Gy or 2 Gy.
Parameters Controls Whole pelvic irradiation
0G y 0 . 5G y 2G y
AUC (min mg/mL) 47256402 38936329* 37116484*
t1/2 (min) 34.769.6 24.763.5 29.967.1
Cmax (mg/mL) 164636 167623 179619
MRT (min) 36.563.0 30.963.7* 25.064.8*
CL (mL/kg/min) 21.361.9 25.862.0* 27.363.6*
Vss (mL/kg) 778688 7756116 670660
AUC: area under the plasma concentration vs. time curve; t1/2: terminal
elimination phase half-life; Cmax: maximum observed plasma concentration;
MRT: mean residence time; CL: total plasma clearance; Vss: volume of
distribution at steady state.
*The mean difference is significant at the 0.05 level in comparison to the control
group.
doi:10.1371/journal.pone.0021000.t001
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(Fig. 4B). When compared with 5-FU alone group, the plasma
levels of MMP-8 increased in both the RT 0.5 Gy followed by 5-
FU (Fig. 4D) and RT 2 Gy followed by 5-FU groups (Fig. 4E) in a
dose-dependent manner by factors of 2.8 and 5.3, respectively.
Intracellular 5-FU levels with or without recombinant
MMP-8 by high performance liquid chromatography
We examined the role of recombinant MMP-8 on intracellular
concentration of 5-FU in HepG2 (Human liver tumor-derived
cells possessing biochemical profiles characteristic of normal
hepatocytes) without receiving radiation. There were no significant
effect on the AUC of 5-FU between the recombinant MMP-8 plus
5-FU and 5-FU alone groups (Fig. 5). We found that recombinant
MMP-8, not induced by irradiation, will not influence intracellular
concentration of 5-FU in liver cells, mimicking a pharmacokinetic
changes at cellular level.
Modulation of 5-FU pharmacokinetic by irradiation was
reversed by MMP-8 inhibitor
We next examined the role of MMP-8 on the effect of RT on 5-
FU pharmacokinetics using an MMP-8 inhibitor. Neither the
MMP-8 inhibitor alone nor its vehicle had a significant effect on
Table 2. The bile of 5-Fluorouracil (100 mg/kg, i.v.)
pharmacokinetics in rats after whole pelvic irradiation with
and without 0.5 and 2 Gy.
Parameters Controls Whole pelvic irradiation
0G y 0 . 5G y 2G y
AUC (min mg/mL) 1180649 1477678* 15406101*
t1/2 (min) 9.260.4 10.360.5 12.962.8
Cmax (mg/mL) 129622 120614 9366.0*
{
MRT (min) 8.961.1 11.160.5* 13.961.3*
{
CL (mL/kg/min) 84.863.6 67.963.6* 65.164.3*
Vss (mL/kg) 7546102 753625 903655*
AUC: area under the plasma concentration vs. time curve; t1/2: terminal
elimination phase half-life; Cmax: maximum observed plasma concentration;
MRT: mean residence time; CL: total plasma clearance; Vss: volume of
distribution at steady state.
*The mean difference is significant at the 0.05 level in comparison to the control
group.
{The mean difference is significant at the 0.05 level between the 0.5 and 2 Gy
groups.
doi:10.1371/journal.pone.0021000.t002
Figure 2. Plasma alanine aminotransferase (ALT) levels in rats of the control, 5-FU-treated only, 2Gy-treated only, 0.5 Gy followed
by 5-FU-treated and 2 Gy followed by 5-FU-treated groups. The serum concentrations of alanine aminotransferase (ALT) levels were not
significantly different between all tested groups. N=5 for each group.
doi:10.1371/journal.pone.0021000.g002
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found that pretreatment with MMP-8 inhibitor significantly
attenuated the decline in AUC of 5-FU caused by pelvic
irradiation (AUCirradiation versus AUCMMP-8 inhibitor+irradiation was
3305 versus 3963 min mg/mL, P,0.05). Moreover, the decreased
MRT and increased clearance value caused by irradiation were
completely reversed by use of the MMP-8 inhibitor (Table 3).
Discussion
After proof of the concept that local RT affected systemic
pharmacokinetics of chemotherapeutics using 5-FU as a model, we
next screened for possible soluble factors responsible for this effect,
which was identified as MMP-8. MMP-8, also known as
collagenase-2 or neutrophil collagenase, is a member of the zinc-
dependent interstitial collagenase subgroup of the MMP family of
neutral proteinases [18]. We demonstrated that MMP-8 possessed
unexpected bioactivity in modulating the pharmacokinetics of 5-
FU.
Polymorphonuclear neutrophils (PMNs) are the main source of
MMP-8 in humans and mice [19,20]. MMP-8 is stored in the
granules of PMNs and is released upon degranulation [21]. Fisher
et al. [22] reported that MMP-8 protein levels in human skin were
increased approximately 4-fold within 8 h and remained elevated
for 24 h after ultraviolet irradiation. Radiation treatment at tumor
bearing sites induces inflammation in the irradiated field and
recruits T lymphocytes, neutrophils, lymphocytes, macrophages,
plasma cells and dendritic cells [18,23,24]. Additionally, irradia-
tion induces up-regulation of the genes of the main proinflamma-
tory chemokines [25]. In the present study, we irradiated the
whole pelvis of rats, which could have delivered a radiation dose to
circulating neutrophils, tissue and bone marrow macrophages and
within the pelvis. Collectively, this raises the possibility that pelvic
irradiation could stimulate neutrophils and/or the other inflam-
matory cell ontogeny, induce inflammatory stress, and enhance
the secretion of MMP-8 (Fig. 4) as well as various other
proinflammatory mediators. Additionally, several studies show
the alterations of plasma substance levels responding to radiation,
such as TGF-b1 [12] and TNF-a [13]. Moreover, TGF-b could be
a target for 5-FU via c-Jun NH2-terminal kinase/activator
protein-1 activation in human fibroblasts [26]. In addition,
TNF-a involves in the regulation of fluoropyrimidine-activating
enzymes, Uridine phosphorylase (UPase), which induces UPase
gene expression with consequent improvement of 5-FU antipro-
liferative activity [27]. However, in the current study, the levels of
TGF-b1 and TNF-a are not increased in the RT alone, 5-FU
alone or RT followed by 5-FU groups when compared with
control group (Fig. 3A and 3B). These data suggest that MMP-8
appears to play a major role in local RT-induced modulation of
systemic 5-FU pharmacokinetics but not through these cytokines.
Harty MW et al. [28] reported that polymorphonuclear cell-
derived MMP8 plays an important role for liver repair in their
reversible biliary obstruction model. The current study shows that
the application of pelvic RT or 5-FU would not cause the damages
of liver function. Thus, the response of MMP-8 induced by RT in
RT-PK phenomena would not be the process of inflammatory
infiltration to liver such as severe damage caused by biliary
obstruction. Besides, there are no differences of viability (data not
show) and intracellular 5-FU levels (Fig. 5) for 5-FU-treated HepG2
with or without recombinant MMP-8. HepG2 cells maintain many
of the morphological and biochemical characteristics of normal
hepatocytes, such as the secretion of most plasma proteins expected
from liver cells, including apolipoprotein B [29]. The result suggests
that recombinant MMP-8, not induced by irradiation, will not
influence the PKs of 5-FU in liver cells and has no significant
toxicity to human hepatoblastoma-derived cell line, HepG2. Taken
together, MMP-8 may not modulate the liver function.
Another important issue is the similar, but lesser, effect of low-
dose RT on 5-FU pharmacokinetics (Fig. 1). Body distribution of
low-dose RT (0.5 Gy, for example) in clinical practice becomes
greatly generous with advanced radiotherapy techniques and
modalities, such as intensity-modulated radiotherapy, helical
Figure 3. The cytokines respond to irradiation (RT) and 5-fluorouracil (5-FU) in plasma for control, RT 2 Gy alone, 5-FU alone, RT 0.5
Gy followed by 5-FU and RT 2 Gy followed by 5-FU groups. (A) The level of transforming growth factor beta 1 (TGF-b1) in plasma. (B) The level
of tumor necrosis factor alpha (TNF-a) in plasma. Each group’s data was collected from five rats.
doi:10.1371/journal.pone.0021000.g003
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therapy and others, in comparison with conventional RT. While
accepting the benefits of targeting the tumors and sparing the
critical organs by using these advanced techniques [30,31], that
one remains cautious the generous, low-dose irradiation could
produce unexpected or unwanted biological effects. Clinically, we
previously observed that low-dose, off-target radiation delivered by
highly conformal tomotherapy could cause severe toxicity to the
critical organs around the targets, such as lungs, and cause
radiation pneumonitis [32]. Yet, the medical community has no
comprehensive understanding regarding the biological effects of
generous, low-dose RT. We hope this study will increase our
knowledge of these effects and provide an experimental model to
understand the biological effects of generous, low-dose RT in the
era of highly conformal RT.
About 80% of 5-FU is catabolyzed by the liver via the
dihydropyrimidine dehydrogenase (DPD) pathway to generate
toxic 5-fluoro-5,6-dihydro-uracil, whereas the anabolic pathway,
via orotate phosphoribosyl transferase, produces active metabolites
including 5-fluorouridine-59-monophosphate, 5-fluorouridine, and
5-fluoro-29-deoxyuridine [33,34]. The overall toxicity was twice as
high in patients with profound DPD deficiencies (,45% of the
mean DPD activity of a control population) when compared to
patients with moderate DPD deficiencies (between 45% and 70%
of the mean DPD activity of a control population), as reported by
Milano and the coauthors [35]. Because 10% to 20% of 5-FU is
excreted unchanged in the urine [36], for patients with renal
dysfunction, the plasma concentration of 5-FU on nondialysis days
is significantly higher than on dialysis days, and this may be due to
the removal of some factors from plasma by hemodialysis, which
inhibit DPD activity [37]. In addition, 5-FU has a relatively
narrow therapeutic index, a strong correlation is described
between exposure to 5-FU and both hematologic and gastrointes-
tinal toxicity [38]. Thus, if the liver or kidneys fall into the
Figure 4. Cytokine profile of rat plasma treated with whole pelvic irradiation. The amount of matrix metalloproteinase-8 (MMP-8)
increased in 0.5-Gy and 2-Gy irradiated groups when compared with the control group. A map of the locations of cytokine antibodies spotted onto
the protein chip is shown on the up side of the Figure. Dotted squares indicate the location of MMP-8. Each cytokine is represented by duplicate
spots in the locations shown. Cytokine antibody arrays assay of (A) untreated control group, (B) whole pelvic irradiation (RT) with 2 Gy only, (C) 5-
fluorouracil (5-FU) alone, (D) RT with 0.5 Gy followed by 5-FU and (E) RT with 2 Gy followed by 5-FU. The cytokine array image represents results of
one of three independent experiments, which show similar patterns of expression.
doi:10.1371/journal.pone.0021000.g004
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of 5-FU [39], may be affected by radiation injury to liver or
kidneys. However, in the current study, the liver and kidneys are
excluded from the whole pelvic irradiation field (Fig. 7). In
addition, the ALT levels were not significantly different between
the control, 5-FU-treated, or pelvic RT groups with or without 5-
FU. (Fig. 2) Thus, the effect of RT on AUC of 5-FU noted in this
study may not be caused by direct modulation of liver function by
RT or 5-FU.
Compared with the control group, whole pelvic irradiation
decreased the AUC of 5-FU in the plasma to a statistically
significantlevel (Fig.1A). Incontrast,irradiation increasedtheAUC
of 5-FU in the bile significantly (Fig. 1B). It was accompanied by a
reduction in MRT and increase in clearance value in the plasma,
butanincreaseinMRTandreductionofclearancevalueinthebile.
With respect to pharmacokinetics, this suggests that pelvic
irradiation could facilitate the excretion of 5-FU.
Given that the concurrent use of chemotherapeutics in
combination with localized conformal RT improves clinical
treatment outcomes for an increasing number of malignancies
[2,3,4,5],ourresults show that both localized target-inandgenerous
target-off irradiation could affect 5-FU pharmacokinetics, and
provides a reason for considering the adjustment of chemothera-
peutic administration during the RT course. The effect of localized
RT on systemic pharmacokinetics of chemotherapeutic agents or
the other drugs clearly needs further clinical evaluation.
Materials and Methods
Materials and reagents
The 5-FU and high-performance liquid chromatography
(HPLC)-grade methanol were purchased from Sigma Chemicals
(St. Louis, MO, USA) and Tedia Company, Inc. (Fairfield, OH,
Figure 5. Intracellular 5-fluorouracil (5-FU) levels for 50 mM 5-FU treated HepG2 (Human liver tumor-derived cells possessing
biochemical profiles characteristic of normal hepatocytes) with or without 10 mg/mL recombinant MMP-8 by high performance
liquid chromatography.
doi:10.1371/journal.pone.0021000.g005
Figure 6. The plasma concentration versus time curve (AUC) of
5-FU post irradiation was reversed by the matrix metallopro-
teinase-8 (MMP-8) inhibitor. The area under the plasma concentra-
tion versus time curve (AUC) of 5-FU 100 mg/kg administered to rats in
the control group without solvent, control group with solvent, whole
pelvic 2-Gy irradiation with solvent, and whole pelvic 2-Gy irradiation
with solvent and MMP-8 inhibitor. The transverse axis illustrates time in
minutes and the vertical axis represents the concentration of 5-FU in
the plasma. Each group’s data was collected from four rats.
doi:10.1371/journal.pone.0021000.g006
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USA) was used for the preparation of solutions and mobile phases.
Animals and sample preparation
Adult, male Sprague-Dawley rats (300620 g body weight) were
provided by the Laboratory Animal Center at National Yang-
Ming University (Taipei, Taiwan). They were housed in a specific
pathogen-free environment and had free access to food (Labora-
tory Rodent Diet 5001, PMI Nutrition International, LLC, MO,
USA) and water. All experimental animal surgery procedures were
reviewed and approved by the animal ethics committee of Mackay
Memorial Hospital, Taipei, Taiwan (MMH-A-S-98011).
Table 3. The plasma of 5-Fluorouracil (5-FU) (100 mg/kg, i.v.) pharmacokinetics in rats treated with and without MMP-8 inhibitor










with solvent and MMP-8
inhibitor
5-FU
AUC (min mg/mL) 42856215* 42856141* 3305628 39636427*
t1/2 (min) 33.3616.1 27.863.0 31.068.8 32.369.9
Cmax (mg/mL) 151617 146635 132651 122629
MRT (min) 3761.7* 3663.7* 2663.8 3662.1*
CL (mL/kg/min) 23.461.1* 23.460.8* 30.360.3 25.462.8*
Vss (mL/kg) 859622 836697 7846110 9116127
AUC: area under the plasma concentration vs. time curve; t1/2: terminal elimination phase half-life; Cmax: maximum observed plasma concentration; MRT: mean
residence time; CL: total plasma clearance; Vss: volume of distribution at steady state.
*The mean difference is significant at the 0.05 level in comparison to the whole pelvic irradiation with solvent and 5-FU group.
doi:10.1371/journal.pone.0021000.t003
Figure 7. Computed tomography was used for simulation of the whole pelvic field. The cranial margin was set at the top of bilateral iliac
crest for the whole pelvic field. Conventional radiotherapy was used to deliver the radiation dose via the anterior-posterior (AP) and PA portals.
doi:10.1371/journal.pone.0021000.g007
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chloralose 0.1 g/ml (1 ml/kg by intraperitoneal injection), and
were immobilized on a board when undergoing computed
tomography for simulation of the whole pelvic field. The cranial
margin was set at the top of the bilateral iliac crests for the whole
pelvic field (Fig. 7). Conventional radiotherapy was used to deliver
the radiation dose via the anterior-posterior (AP) and PA portals.
The experimental animals were randomized to the control, 2-Gy
alone, 5-FU alone, 0.5-Gy followed by 5-FU, and 2-Gy followed
by 5-FU groups. Each group’s data was collected from six rats.
Allometric scaling of the radiation doses (0.5 and 2 Gy) between
humans and rats, respectively, was an important consideration in
the study. The reason for the use of 0.5 and 2 Gy for the rats was
to simulate the relevant dosage range for daily treatment of the
human torso, for safety and workability, as previously reported
[16]. Briefly, there was no direct comparison of allometric scaling
using whole pelvic irradiation. Nonetheless, the allometric scaling
of the lethal dose (LD50) (Gy) of total-body irradiation for humans
and rats is 4 Gy and 6.75 Gy, respectively [40]. Given that this
difference is moderate, we decided to use 0.5 and 2 Gy for rats to
simulate the relevant dose range for daily treatment of the human
torso.
Ambre et al. [41] studied the elimination of 5-FU and its
metabolites after intravenous administration of 5-FU at 15 and
150 mg/kg to rats. The results of that study suggested that
saturation of the catabolic pathway occurred after the higher dose.
Jarugula et al. [42] proved that the dose-normalized area under the
curve (AUC) was significantly higher after administration of
100 mg/kg (mean 6 standard deviation, SD, 1.1460.55 mg?h/
L/mg) than after 50 mg/kg (mean 6 SD, 0.5060.16 mg?h/L/
mg) or 10 mg/kg (mean 6 SD, 0.4360.11 mg?h/L/mg). Thus,
we chose 100 mg/kg as a feasible 5-FU dose in rats for
examination of 5-FU pharmacokinetic parameters, based on
previous reports [16,41,42].
Twenty hours after RT, the rats were administered 100 mg/kg
of 5-FU in 2 mL of normal saline by intravenous infusion into the
femoral vein over a 2-min period [42]. A 150-mL blood sample
was withdrawn from the jugular vein with a fraction collector
according to a programmed schedule at 5, 15, 30, 45, and 60 min,
and 1.5, 2, 2.5, and 3 h following drug administration. The blood
samples were immediately centrifuged at 33006g for 10 min. The
resulting plasma (50 mL) was added to 1 mL of ethyl acetate in a
clean tube, vortexed for 5 min, and centrifuged at 59006g for
10 min. After centrifugation, the upper organic layer containing
the ethyl acetate was transferred to a new tube and evaporated to
dryness under flowing nitrogen. The dried residue was reconsti-
tuted with 50 mL of Milli-Q water (Millipore). A 20-mL aliquot of
the solution was injected to the high performance liquid
chromatography-ultraviolet (HPLC-UV) detection system.
High performance liquid chromatography
Chromatographic analysis was performed on a Model LC-
20AT HPLC system (Shimadzu, Tokyo, Japan) equipped with a
Model SPD-20A wavelength UV detector, SIL-20AC autosam-
pler, and an LC Solution data processing system. A LiChroCART
RP-18e column (Purospher, 250 mm, 5 mm, Merck, Darmstadt,
Germany) with a LiChroCART 4-4 guard column was used for
separation. The mobile phase comprised 10 mM potassium
phosphate-methanol (99:1, v/v, pH 4.5 adjusted by 85% phos-
phoric acid), and the flow rate of the mobile phase was 1 ml/min.
The detection wavelength was set at 266 nm. Under these
conditions, the retention time of 5-FU was 5.4 min. The linearity
of calibration curves was demonstrated by the good determination
coefficients (r
2) obtained for the regression line. Good linearity was
achieved over the range of 0.01–5 mg/ml, with all coefficients of
correlation greater than 0.998. All samples were freshly prepared,
including the standard solutions, from the same stock solution
(5 mg/mL). The 0.01-mg/mL limit of quantification was defined
the lowest concentration on the calibration curve that could be
measured routinely with acceptable bias and relative SD. The
overall mean precision, defined by the relative SD, ranged from
0.2% to 11.0%. Analytical accuracy was expressed as the
percentage difference of the mean observed values compared to
known concentrations varying from 210.0% to 14.0%. The
recovery results for concentrations of 0.1–10 mg/mL were 92.0%–
94.0%
Evaluation of hepatic functions
The plasma levels of alanine aminotransferase (ALT) were
measured to check the influence of different modalities for hepatic
function by a standard colorimetric method using a Synchron
LX20 spectrophotometer (Beckman Coulter) and manufacturer-
supplied reagents.
Serum cytokine analysis
The plasma levels of cytokines (transforming growth factor beta
1 (TGF-b1) and tumor necrosis factor alpha (TNF-a)) obtained
from the mouse blood samples were analyzed using enzyme-linked
immunosorbent assay (ELISA) (R&D Systems) according to the
manufacturer’s instructions.
Cytokine antibody array
The rat plasma samples were analyzed using the a cytokine
antibody array (RayBioH Mouse Cytokine Antibody Arrays II,
RayBiotech, Inc., Norcross, Ga.) according to the manufacturer’s
instructions and as previously described [43] to detect possible
mediators of the 5-FU–RT interaction. This particular array
simultaneously detects 34 murine cytokines. (Fig. 4) Briefly,
cytokine array membranes were blocked in 2 ml of 16 blocking
buffer for 30 min and then incubated with 1 ml of plasma sample
at room temperature for 1–2 h. Samples were then decanted from
each container, and the membranes were washed three times with
2m lo fl 6wash buffer I, followed by two washes with 2 ml of l6
wash buffer II at room temperature with shaking. Membranes
were then incubated in 1:250 diluted biotin-conjugated primary
antibodies at room temperature for 1–2 h and washed as
described above, before incubation in 1:1000 diluted horseradish
peroxidase (HRP)-conjugated streptavidin. After incubation in
HRP-conjugated streptavidin for 30–60 min, membranes were
washed thoroughly and exposed to a peroxide substrate (detection
buffers C and D, RayBiotech, Inc.) for 5 min in the dark before
imaging. Membranes then were exposed to X-ray film (Kodak X-
OMAT AR film) at room temperature for 1 minute. Signal
intensities were analyzed with Fuji Film Multi Gauge V2.1. Biotin-
conjugated IgG served as a positive control at six spots, where it
was used to identify membrane orientation and to normalize the
results from different membranes that were being compared. For
each spot, the net optical density was determined by subtracting
the background optical density from the total raw optical density
and the optical density of each cytokine was represented as a
percentage of the positive control.
Determination of intracellular 5-FU levels with or without
recombinant MMP-8 by high performance liquid
chromatography
To examine the effect of MMP-8 on normal liver cells, a human
hepatoblastoma-derived cell line, HepG2, was used to simulate
RT Modulate the PK of 5-FU
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with 10 mg/mL recombinant MMP-8 plus 50 mM 5-FU or 50 mM
5-FU alone, HepG2 (Human hepatocellular carcinoma cell line)
cells were collected every 10 min until 60 min and washed twice in
phosphate-buffered saline (PBS) followed by centrifugation at
13000 rpm for 5 min. To extract intracellular 5-FU, an extraction
solution containing 0.1% Triton X-100 in dimethyl sulfoxide was
added to the cell pellets, and this suspension was vortexed and
centrifuged at13000 rpm for 5 min. The resulting solution was
mixed with an equal volume of acetonitrile for deproteination.
The protein precipitates were removed by centrifugation
(13000 rpm for 5 min), and a 20 mL aliquot of the supernatant
was subjected to high performance liquid chromatography analysis
as mention before.
Mediator inhibitor preparation and experiment
MMP-8 inhibitor I (Calbiochem, La Jolla, CA) was adminis-
tered to the rats to examine whether or not RT modulation of 5-
FU pharmacokinetic parameters could be blocked. Briefly, MMP-
8 inhibitor I was dissolved in PEG400/ethanol [4:1 (v/v)] solution,
yielding a final concentrations of 5 mg/mL. Two hours before
irradiation, 10 mg/kg of MMP-8 inhibitor I was infused into the
rat’s tail vein over a 2-min period. After that, the rats were
anesthetized with urethane 1 g/ml and a-chloralose 0.1 g/ml
(1 ml/ kg by intraperitoneal injection), and were immobilized on a
board to undergo computed tomography for simulation of the
whole pelvic field and received irradiation, as described previously.
The experimental animals were randomized to control without
PEG400/ethanol [4:1 (v/v)] solution (0 Gy), control with solvent
(0 Gy), whole pelvic irradiation (2 Gy) with solvent and whole
pelvic irradiation (2 Gy) with MMP-8 inhibitor and solvent groups,
respectively. After RT sham RT 20 hrs, all rats received 5-FU
(100 mg/kg) injections and the pharmacokinetic parameters of 5-
FU were analyzed. Each group’s data was collected from four rats.
Pharmacokinetics and data analysis
Pharmacokinetic parameters including the AUC for concentra-
tion versus time, terminal elimination phase t1/2, Cmax, MRT,
total plasma clearance and Vss were calculated using the
pharmacokinetics calculation software WinNonlin Standard
Edition, Version 1.1 (Scientific Consulting, Apex, NC, USA)
using a compartmental method.
Statistical methods
The results are presented as means 6 standard deviations.
Differences in actuarial outcomes between the groups were
calculated using one-way analysis of variance (ANOVA), with
post hoc multiple comparisons. All analyses were performed using
the SPSS, version 12.0 (SPSS, Chicago, IL, USA).
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